Sirona Biochem Corp. (SRBCF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.33 Million CAD | 19.0% |
| 2022 | -3.51 Million CAD | -54.54% |
| 2021 | -2.29 Million CAD | 44.68% |
| 2020 | -4.11 Million CAD | 7.29% |
| 2019 | - CAD | -387.24% |
| 2018 | -911.98 Thousand CAD | 60.42% |
| 2017 | -2.3 Million CAD | 17.26% |
| 2016 | -2.78 Million CAD | 15.19% |
| 2015 | -3.39 Million CAD | 4.79% |
| 2014 | -3.45 Million CAD | -36.97% |
| 2013 | -2.51 Million CAD | 13.14% |
| 2012 | -2.89 Million CAD | -38.49% |
| 2011 | -2.09 Million CAD | -96.13% |
| 2010 | -1.06 Million CAD | 12.78% |
| 2009 | -1.22 Million CAD | -845.19% |
| 2008 | -129.45 Thousand CAD | 45.62% |
| 2007 | -238.06 Thousand CAD | -3967650.0% |
| 2006 | -6.00 CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -531.58 Thousand CAD | 36.02% |
| 2024 Q1 | -777.72 Thousand CAD | -15.14% |
| 2024 Q3 | -662.3 Thousand CAD | -58.0% |
| 2023 Q2 | -755.14 Thousand CAD | -22.17% |
| 2023 FY | - CAD | 19.0% |
| 2023 Q1 | -618.12 Thousand CAD | -71.58% |
| 2023 Q4 | -568.88 Thousand CAD | -26.1% |
| 2023 Q3 | -451.14 Thousand CAD | 40.26% |
| 2022 Q4 | -360.25 Thousand CAD | 4.98% |
| 2022 Q3 | -379.13 Thousand CAD | 49.83% |
| 2022 FY | - CAD | -54.54% |
| 2022 Q1 | -2.02 Million CAD | -478.97% |
| 2022 Q2 | -755.73 Thousand CAD | 62.72% |
| 2021 Q1 | -660.54 Thousand CAD | -63.25% |
| 2021 FY | - CAD | 44.68% |
| 2021 Q2 | -774.01 Thousand CAD | -17.18% |
| 2021 Q4 | -350.11 Thousand CAD | 72.24% |
| 2021 Q3 | -1.26 Million CAD | -62.92% |
| 2020 Q3 | -618 Thousand CAD | 1.73% |
| 2020 Q4 | -404.62 Thousand CAD | 34.53% |
| 2020 Q2 | -628.9 Thousand CAD | 74.64% |
| 2020 Q1 | -2.48 Million CAD | -93.92% |
| 2020 FY | - CAD | 7.29% |
| 2019 Q2 | -1.27 Million CAD | -136.48% |
| 2019 Q3 | -1.34 Million CAD | -5.7% |
| 2019 FY | - CAD | -387.24% |
| 2019 Q4 | -1.27 Million CAD | 5.19% |
| 2019 Q1 | -539.63 Thousand CAD | -15.62% |
| 2018 FY | - CAD | 60.42% |
| 2018 Q4 | -466.75 Thousand CAD | -387.53% |
| 2018 Q1 | -69.07 Thousand CAD | 88.4% |
| 2018 Q2 | -564.28 Thousand CAD | -716.98% |
| 2018 Q3 | 162.33 Thousand CAD | 128.77% |
| 2017 FY | - CAD | 17.26% |
| 2017 Q3 | -550.93 Thousand CAD | 15.69% |
| 2017 Q2 | -653.46 Thousand CAD | -29.56% |
| 2017 Q1 | -504.36 Thousand CAD | 42.15% |
| 2017 Q4 | -595.22 Thousand CAD | -8.04% |
| 2016 Q2 | -345.87 Thousand CAD | 51.6% |
| 2016 Q4 | -871.81 Thousand CAD | -2.32% |
| 2016 Q3 | -852.01 Thousand CAD | -146.33% |
| 2016 FY | - CAD | 15.19% |
| 2016 Q1 | -714.56 Thousand CAD | -123.16% |
| 2015 FY | - CAD | 4.79% |
| 2015 Q1 | -997.53 Thousand CAD | -112.36% |
| 2015 Q4 | -320.2 Thousand CAD | 70.91% |
| 2015 Q3 | -1.1 Million CAD | -29.41% |
| 2015 Q2 | -850.48 Thousand CAD | 14.74% |
| 2014 FY | - CAD | -36.97% |
| 2014 Q4 | -469.73 Thousand CAD | 29.34% |
| 2014 Q3 | -664.81 Thousand CAD | 48.91% |
| 2014 Q2 | -1.3 Million CAD | -35.59% |
| 2014 Q1 | -959.68 Thousand CAD | -66.64% |
| 2013 Q4 | -575.88 Thousand CAD | 1.41% |
| 2013 FY | - CAD | 13.14% |
| 2013 Q2 | -687.89 Thousand CAD | -3.95% |
| 2013 Q1 | -661.72 Thousand CAD | 36.36% |
| 2013 Q3 | -584.13 Thousand CAD | 15.08% |
| 2012 Q3 | -549.67 Thousand CAD | 25.42% |
| 2012 Q2 | -737.01 Thousand CAD | -45.16% |
| 2012 FY | - CAD | -38.49% |
| 2012 Q1 | -507.74 Thousand CAD | 49.72% |
| 2012 Q4 | -1.03 Million CAD | -89.18% |
| 2011 Q2 | -502.11 Thousand CAD | -9.03% |
| 2011 Q3 | -477.38 Thousand CAD | 4.93% |
| 2011 Q1 | -460.53 Thousand CAD | 3.38% |
| 2011 FY | - CAD | -96.13% |
| 2011 Q4 | -1 Million CAD | -111.52% |
| 2010 Q1 | -202.01 Thousand CAD | 28.22% |
| 2010 Q4 | -476.61 Thousand CAD | -127.73% |
| 2010 Q2 | -178.92 Thousand CAD | 11.43% |
| 2010 Q3 | -209.29 Thousand CAD | -16.98% |
| 2010 FY | - CAD | 12.78% |
| 2009 Q2 | -666.44 Thousand CAD | -790.61% |
| 2009 Q3 | -200.87 Thousand CAD | 69.86% |
| 2009 FY | - CAD | -845.19% |
| 2009 Q4 | -281.44 Thousand CAD | -40.11% |
| 2009 Q1 | -74.83 Thousand CAD | -115.07% |
| 2008 Q4 | -34.79 Thousand CAD | -53.88% |
| 2008 Q3 | -22.61 Thousand CAD | 52.3% |
| 2008 FY | - CAD | 45.62% |
| 2008 Q1 | -24.75 Thousand CAD | 18.15% |
| 2008 Q2 | -47.4 Thousand CAD | -91.46% |
| 2007 FY | - CAD | -3967650.0% |
| 2007 Q3 | -23.32 Thousand CAD | 39.87% |
| 2007 Q1 | -145.69 Thousand CAD | 0.0% |
| 2007 Q4 | -30.24 Thousand CAD | -29.66% |
| 2007 Q2 | -38.79 Thousand CAD | 73.37% |
| 2006 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 96.716% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 60.654% |
| SQZ Biotechnologies Company | -64.14 Million USD | 96.363% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 86.57% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 102.481% |
| Mesoblast Limited | -62.38 Million USD | 96.261% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -51.869% |
| Genus plc | 73.7 Million USD | 103.165% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 64.716% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 34.232% |
| Marizyme, Inc. | -34.28 Million USD | 93.195% |
| ContraFect Corporation | -64.99 Million USD | 96.411% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 73.406% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 48.46% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -66.413% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 11.786% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -0.386% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -350.304% |
| Accustem Sciences Inc. | -3.74 Million USD | 37.733% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 95.163% |
| EV Biologics, Inc. | -1.26 Million USD | -84.1% |
| Q BioMed Inc. | -617.62 Thousand USD | -277.7% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 165.308% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -268.874% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -2.114% |
| Biomind Labs Inc. | -1.03 Million USD | -125.488% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 123.618% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 67.425% |
| Skye Bioscience, Inc. | -13.54 Million USD | 82.781% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -56.835% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -9231.136% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 39.944% |
| IMV Inc. | -35.52 Million USD | 93.433% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 85.3% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 6.762% |
| GB Sciences, Inc. | -1.41 Million USD | -64.294% |
| Alpha Cognition Inc. | -9.7 Million USD | 75.965% |
| HST Global, Inc. | -5303.00 USD | -43889.893% |
| CSL Limited | 4.78 Billion USD | 100.049% |
| Halberd Corporation | -74.27 Thousand USD | -3040.57% |
| Enzolytics Inc. | -2.12 Million USD | -9.932% |
| Resverlogix Corp. | -11.74 Million USD | 80.133% |
| Affymax, Inc. | -14.29 Million USD | 83.681% |
| SYBLEU INC | -141.57 Thousand USD | -1547.784% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 23.84% |
| argenx SE | -216.02 Million USD | 98.92% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 95.785% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 291.683% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -55.632% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 715.764% |
| AVAX Technologies, Inc. | -6.11 Million USD | 61.837% |
| Zenith Capital Corp. | -8.6 Million USD | 72.894% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.062% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -13290.643% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 4.647% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1225.262% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 94.115% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 19.346% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -122.953% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 34793.397% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -33.302% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -21.442% |
| BioStem Technologies, Inc. | -7.55 Million USD | 69.117% |
| ONE Bio Corp. | 13.61 Million USD | 117.136% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1188.205% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -13.407% |
| Agentix Corp. | -1.37 Million USD | -70.058% |
| LadRx Corporation | 412.28 Thousand USD | 665.821% |
| Cell Source, Inc. | -4.27 Million USD | 45.4% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -535.253% |
| Regen BioPharma, Inc. | 1.46 Million USD | 259.131% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -148.977% |
| NovAccess Global Inc. | -1.03 Million USD | -125.434% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 126.348% |
| Itoco Inc. | -1.86 Million USD | -24.815% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -514.505% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -109.031% |
| Kadimastem Ltd | -2.62 Million USD | 11.111% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -875.448% |
| CytoDyn Inc. | -18.02 Million USD | 87.061% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -2851.808% |
| Mobile Lads Corp. | -2.24 Million USD | -4.088% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -18975.836% |
| Qrons Inc. | -40.08 Thousand USD | -5720.174% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -380.315% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 542.29% |
| Rebus Holdings, Inc. | -951 Thousand USD | -145.298% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -119.657% |
| International Stem Cell Corporation | 202 Thousand USD | 1254.844% |
| Bioxytran, Inc. | -3.82 Million USD | 38.935% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4331.581% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 5.246% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 93.496% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -5083.964% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 14.8% |
| Neutra Corp. | -181.24 Thousand USD | -1187.075% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 88.428% |
| PureTech Health plc | -11.62 Million USD | 79.936% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 88.427% |
| IXICO plc | -707 Thousand USD | -229.955% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 69.645% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 95.175% |
| CSL Limited | 4.73 Billion USD | 100.049% |
| Cellectis S.A. | -92.63 Million USD | 97.482% |